Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag add-on therapy in children and adolescents with pulmonary arterial hypertension
MOH_2020-08-11_008984Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Selexipag with Placebo (2 arms). Primary endpoint: Not reported. Started Jul 2020; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2020-08-11_008984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-08-11_008984.